These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 18657401

  • 21. Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.
    Di Fabio R, Griffante C, Alvaro G, Pentassuglia G, Pizzi DA, Donati D, Rossi T, Guercio G, Mattioli M, Cimarosti Z, Marchioro C, Provera S, Zonzini L, Montanari D, Melotto S, Gerrard PA, Trist DG, Ratti E, Corsi M.
    J Med Chem; 2009 May 28; 52(10):3238-47. PubMed ID: 19388677
    [Abstract] [Full Text] [Related]

  • 22. Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies.
    Juszczak M, Boczek-Leszczyk E, Stempniak B.
    J Physiol Pharmacol; 2007 Dec 28; 58(4):829-43. PubMed ID: 18195491
    [Abstract] [Full Text] [Related]

  • 23. Discovery and stereoselective synthesis of the novel isochroman neurokinin-1 receptor antagonist 'CJ-17,493'.
    Shishido Y, Wakabayashi H, Koike H, Ueno N, Nukui S, Yamagishi T, Murata Y, Naganeo F, Mizutani M, Shimada K, Fujiwara Y, Sakakibara A, Suga O, Kusano R, Ueda S, Kanai Y, Tsuchiya M, Satake K.
    Bioorg Med Chem; 2008 Aug 01; 16(15):7193-205. PubMed ID: 18640044
    [Abstract] [Full Text] [Related]

  • 24. Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate.
    Di Fabio R, Alvaro G, Griffante C, Pizzi DA, Donati D, Mattioli M, Cimarosti Z, Guercio G, Marchioro C, Provera S, Zonzini L, Montanari D, Melotto S, Gerrard PA, Trist DG, Ratti E, Corsi M.
    J Med Chem; 2011 Feb 24; 54(4):1071-9. PubMed ID: 21229983
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry.
    Ebner K, Muigg P, Singewald G, Singewald N.
    Ann N Y Acad Sci; 2008 Nov 24; 1144():61-73. PubMed ID: 19076365
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Anxiogenic effects of activation of NK-1 receptors of the dorsal periaqueductal gray as assessed by the elevated plus-maze, ultrasound vocalizations and tail-flick tests.
    Bassi GS, Nobre MJ, de Araújo JE, Brandão ML.
    Neuropeptides; 2007 Dec 24; 41(6):365-74. PubMed ID: 17981325
    [Abstract] [Full Text] [Related]

  • 31. Neurokinin-1 receptor antagonism by SR140333: enhanced in vivo ACh in the hippocampus and promnestic post-trial effects.
    Kart E, Jocham G, Müller CP, Schlömer C, Brandão ML, Huston JP, de Souza Silva MA.
    Peptides; 2004 Nov 24; 25(11):1959-69. PubMed ID: 15501528
    [Abstract] [Full Text] [Related]

  • 32. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
    Tsuchida H, Takahashi S, Nosaka E, Mukaiyama O, Yamashita M, Morimoto K.
    Eur J Pharmacol; 2008 May 31; 586(1-3):306-12. PubMed ID: 18353309
    [Abstract] [Full Text] [Related]

  • 33. Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy.
    Lindström E, von Mentzer B, Påhlman I, Ahlstedt I, Uvebrant A, Kristensson E, Martinsson R, Novén A, de Verdier J, Vauquelin G.
    J Pharmacol Exp Ther; 2007 Sep 31; 322(3):1286-93. PubMed ID: 17575073
    [Abstract] [Full Text] [Related]

  • 34. Pharmacological properties of FK886, a new, centrally active neurokinin-1 receptor antagonist.
    Yoshino-Furukawa T, Maeda Y, Kikuchi A, Sakuma H, Imazumi K, Yamakuni H, Sogabe H, Matsuo M, Manda T, Uchida W.
    Biol Pharm Bull; 2013 Sep 31; 36(1):76-81. PubMed ID: 23302639
    [Abstract] [Full Text] [Related]

  • 35. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
    Miike T, Shirahase H, Kanda M, Kunishiro K, Kurahashi K.
    Vascul Pharmacol; 2009 Sep 31; 51(2-3):147-53. PubMed ID: 19539781
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Inhibition of substance P-induced defensive behavior via neurokinin-1 receptor antagonism in the central and medial but not basolateral nuclei of the amygdala in male Wistar rats.
    Bassi GS, Carvalho MC, Almada RC, Brandão ML.
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jul 03; 77():146-154. PubMed ID: 28390968
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors.
    Engberg S, Ahlstedt I, Leffler A, Lindström E, Kristensson E, Svensson A, Påhlman I, Johansson A, Drmota T, von Mentzer B.
    Biochem Pharmacol; 2007 Jan 15; 73(2):259-69. PubMed ID: 17097619
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.